Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following the December 2025 commercial launch of LYMPHIR. For FQ1 2026, the company reported $3.9 million in consolidated revenue, reflecting initial sales through a nationwide network of specialty distributors. This was achieved via Citius Pharma’s majority-owned subsidiary, Citius Oncology, Inc., which introduced the targeted immunotherapy for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma.

The launch of LYMPHIR is being supported by an AI-enabled commercial platform designed to target a concentrated prescriber base and enhance patient access. Beyond the US market, Citius Oncology has negotiated agreements with regional partners to enable access in parts of Europe and the Middle East through Named Patient Programs. The company is also exploring future label expansion opportunities through investigator-initiated Phase I studies, which are evaluating LYMPHIR’s potential in combination with pembrolizumab for solid tumors and as part of lymphodepletion regimens before CAR-T therapy.

For FQ1, Citius Pharma reported a net loss of $8.2 million, an improvement over the $9.8 million loss in the prior-year period. The company ended the quarter with $7.7 million in cash and cash equivalents, having raised ~$20.9 million in net proceeds from equity financings. While focusing on the LYMPHIR rollout, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) continues to advance its late-stage pipeline, which includes Mino-Lok, an antibiotic lock solution for catheter-related infections, and Halo-Lido, a topical formulation for hemorrhoids, both of which remain under active engagement with the FDA.

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is a biopharmaceutical company that develops and commercializes critical care products. The company’s LYMPHIR, which is an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.

While we acknowledge the potential of CTXR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Stocks With Explosive Growth Potential.

Disclosure: None. Follow Insider Monkey on Google News.